Return to study ST001943 main page
MB Sample ID: SA184327
| Local Sample ID: | QC_CC_3 |
| Subject ID: | SU002035 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 53 ± 15 |
| Weight Or Weight Range: | 116 ± 25 |
| Gender: | Male and female |
| Human Inclusion Criteria: | (i) body mass index (BMI)>35kg/m2 plus GFR 30–60ml/min and proteinuria >1 g/24h or GFR>60ml/min and proteinuria >2.5 g/24h despite receiving maximally tolerated doses of renin-angiotensin-aldosterone system (RAAS) blocker and (ii) BMI>40kg/m2 with a GFR>30ml/min and proteinuria >0.5 g/24h despite receiving maximally tolerated doses of RAAS blocker. For the renal function criterion, eGFR was used. The follow-up time was 24 months. |
| Human Exclusion Criteria: | 1) Patients who had participated or were participating in another clinical trial or had taken an experimental drug in the last 28 days. 2) Patients with renal transplantation and/or chronic replacement therapy (hemodialysis and/or peritoneal dialysis). 3) Subjects with poorly controlled blood pressure (SBP > 170 mmHg or DBP > 110 mmHg). 4) Patients with a history of cardiovascular events in the past six months. 5) Patients treated with immunosuppressants. 6) Subjects with a history of renovascular disease, autoimmune diseases, cancer, drug use, or obstructive uropathy. 6) Patients who did not sign the informed consent. 7) Patients who were pregnant or lactating. eGFR was used to establish the renal function criteria. Patients were monitored for 24 months. |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN003187 |
|---|---|
| Analysis type | MS |
| Chromatography type | None (Direct infusion) |
| Chromatography system | none |
| Column | none |
| MS Type | EI |
| MS instrument type | CE-TOF-MS |
| MS instrument name | Agilent 6224 TOF |
| Ion Mode | POSITIVE |
| Units | Area |
